Hydromorphone: Evolving to Meet the Challenges of Today's Health Care Environment

Clinical Therapeutics

Volumn 35, Issue 12, 2013, Pages 2007-2027

  Gregory, Thomas B ^a  

^a TRUMAN MEDICAL CENTER   (United States)

Author keywords

Extended release; Hydromorphone; Opioids; Pain

Indexed keywords

BUPIVACAINE; BUPRENORPHINE; CLONIDINE; CODEINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; KETAMINE; METHADONE; MORPHINE; OXYCODONE; OXYMORPHONE; PETHIDINE; SUFENTANIL; TRAMADOL;

ANALGESIA; ANALGESIC ACTIVITY; ARTHRALGIA; BONE PAIN; CANCER PAIN; CHRONIC PAIN; CONSTIPATION; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG METABOLISM; DRUG MISUSE; DRUG OVERDOSE; DRUG POTENCY; DRUG RELEASE; DRUG SOLUBILITY; DYSPHORIA; EUPHORIA; HEALTH CARE; HUMAN; LONG TERM CARE; LOW BACK PAIN; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PAIN; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; STEADY STATE; TOOTH PAIN; VOMITING;

EXTENDED-RELEASE; HYDROMORPHONE; OPIOIDS; PAIN;

ANALGESICS, OPIOID; DOSAGE FORMS; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROMORPHONE; OPIOID-RELATED DISORDERS; PAIN; PAIN MANAGEMENT; PATIENT SELECTION; UNITED STATES;

EID: 84890312747     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.09.027     Document Type: Review

References (97)

1. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 2002, (1):CD003447.
2. Murray A., Hagen N.A. Hydromorphone. J Pain Symptom Manage 2005, 29:S57-S66.
3. Kilgore E. Exalgo hydromorphone ER: efficacy and safety review. Silver Spring, Md: US Food and Drug Administration; 2009. Joint Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committee. Accessed April 30, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM248768.pdf.
4. FDA asks Purdue Pharma to withdraw Palladone for safety reasons [press release]. July 13, 2005. Silver Spring, Md: US Food and Drug Administration. Accessed April 30, 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108460.htm.
5. Murray S., Wooltorton E. Alcohol-associated rapid release of a long-acting opioid. CMAJ 2005, 173:756.
6. Exalgo (hydromorphone HCl) extended-release tablets [package insert]. Hazelwood, Mo: Mallinckrodt Brand Pharmaceuticals, Inc; 2012.
7. Neuromed Pharmaceuticals Ltd. Exalgo (hydromorphone HCl) extended-release tablets CII: advisory committee briefing document. NDA 21-217. Accessed April 30, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM183035.pdf.
8. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research. Division Director Summary Review for Regulatory Action: Exalgo (hydromorphone HCl) Extended Release. Silver Spring, Md: US Food and Drug Administration; 2010. NDA 21-217. Accessed April 30, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021217s000sumr.pdf.
9. Knotkova H., Fine P.G., Portenoy R.K. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 2009, 38:426-439.
10. Trescot A.M., Helm S., Hansen H., et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008, 11:S5-S62.
11. Sarhill N., Walsh D., Nelson K.A. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001, 9:84-96.
12. Collett B.J. Opioid tolerance: the clinical perspective. Br J Anaesth 1998, 81:58-68.
13. Vallejo R., Barkin R.L., Wang V.C. Pharmacology of opioids in the treatment of chronic pain syndromes. Pain Physician 2011, 14:E343-E360.
14. Smith H.S. Opioid metabolism. Mayo Clin Proc 2009, 84:613-624.
15. Turgeon J., Groning R., Sathyan G., et al. The pharmacokinetics of a long-acting OROS hydromorphone formulation. Expert Opin Drug Deliv 2010, 7:137-144.
16. Babul N., Darke A.C., Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 1995, 10:184-186.
17. Wright A.W., Mather L.E., Smith M.T. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001, 69:409-420.
18. Wright A.W., Nocente M.L., Smith M.T. Hydromorphone-3-glucuronide: biochemical synthesis and preliminary pharmacological evaluation. Life Sci 1998, 63:401-411.
19. Smith M.T. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000, 27:524-528.
20. Hagen N., Swanson R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies. J Pain Symptom Manage 1997, 14:51-58.
21. Otton S.V., Schadel M., Cheung S.W., et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993, 54:463-472.
22. Neafsey P., Ginsberg G., Hattis D., Sonawane B. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev 2009, 12:334-361.
23. World Health Organization. Cancer pain relief: with a guide to opioid availability. Geneva, Switzerland: World Health Organization; 1996. Accessed January 11, 2013. http://whqlibdoc.who.int/publications/9241544821.pdf.
24. Ambrosio F., Paoletti F., Savoia G., et al. SIAARTI recommendations on the assessment and treatment of chronic cancer pain. Minerva Anestesiol 2003, 69:629-697.
25. Caraceni A., Hanks G., Kaasa S., et al. European Palliative Care Research Collaborative; European Association for Palliative Care. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012, 13:e58-e68.
26. Deer T.R., Smith H.S., Burton A.W., et al. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician 2011, 14:E283-E312.
27. Trescot A.M., Boswell M.V., Atluri S.L., et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006, 9:1-39.
28. Pergolizzi J., Boger R.H., Budd K., et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008, 8:287-313.
29. Dilaudid Injection (hydromorphone hydrochloride) and Dilaudid-HP Injection (hydromorphone hydrochloride) [package insert]. Stamford, Conn: Purdue Pharma, LP; 2011.
30. Moulin D.E., Kreeft J.H., Murray-Parsons N., Bouquillon A.I. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet 1991, 337:465-468.
31. Fudin J., Smith H.S., Toledo-Binette C.S., et al. Use of continuous ambulatory infusions of concentrated subcutaneous (s.q.) hydromorphone versus intravenous (i.v.) morphine: cost implications for palliative care. Am J Hosp Palliat Care 2000, 17:347-353.
32. Slatkin N.E., Rhiner M. Ketamine in the treatment of refractory cancer pain: case report, rationale, and methodology. J Support Oncol 2003, 1:287-293.
33. Miller M.G., McCarthy N., O'Boyle C.A., Kearney M. Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial. J Pain Symptom Manage 1999, 18:9-16.
34. Rapp S.E., Egan K.J., Ross B.K., et al. A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia. Anesth Analg 1996, 82:1043-1048.
35. Chan W.H., Lin C.J., Sun W.Z., et al. Comparison of subcutaneous hydromorphone with intramuscular meperidine for immediate postoperative analgesia. Kaohsiung J Med Sci 1999, 15:419-427.
36. Chang A.K., Bijur P.E., Baccelieri A., Gallagher E.J. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial. Am J Geriatr Pharmacother 2009, 7:1-10.
37. Chang A.K., Bijur P.E., Meyer R.H., et al. Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: a randomized clinical trial. Ann Emerg Med 2006, 48:164-172.
38. Chang A.K., Bijur P.E., Napolitano A., et al. Two milligrams i.v. hydromorphone is efficacious for treating pain but is associated with oxygen desaturation. J Opioid Manag 2009, 5:75-80.
39. Liu S.S., Bieltz M., Wukovits B., John R.S. Prospective survey of patient-controlled epidural analgesia with bupivacaine and hydromorphone in 3736 postoperative orthopedic patients. Reg Anesth Pain Med 2010, 35:351-354.
40. Ackerman L.L., Follett K.A., Rosenquist R.W. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage 2003, 26:668-677.
41. Rathmell J.P., Lair T.R., Nauman B. The role of intrathecal drugs in the treatment of acute pain. Anesth Analg 2005, 101:S30-S43.
42. Rauch E. Intrathecal hydromorphone for cesarean delivery: in search of improved postoperative pain management: a case report. AANA J 2011, 79:427-432.
43. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology 2012, 116:248-273. American Society of Anesthesiologists Task Force on Acute Pain Management.
44. Chestnut D.H., Choi W.W., Isbell T.J. Epidural hydromorphone for postcesarean analgesia. Obstet Gynecol 1986, 68:65-69.
45. Halpern S.H., Arellano R., Preston R., et al. Epidural morphine vs hydromorphone in post-caesarean section patients. Can J Anaesth 1996, 43:595-598.
46. Henderson S.K., Matthew E.B., Cohen H., Avram M.J. Epidural hydromorphone: a double-blind comparison with intramuscular hydromorphone for postcesarean section analgesia. Anesthesiology 1987, 66:825-830.
47. Shulman M.S., Wakerlin G., Yamaguchi L., Brodsky J.B. Experience with epidural hydromorphone for post-thoracotomy pain relief. Anesth Analg 1987, 66:1331-1333.
48. Dilaudid (hydromorphone hydrochloride) oral liquid and tablets [package insert]. Stamford, Conn: Purdue Pharma LP; 2008.
49. Goldberg R.I., Shuman F.I. Oral hydromorphone in trauma. Curr Ther Res Clin Exp 1965, 7:284-288.
50. Cass L.J., Frederik W.S. A controlled clinical evaluation of the analgesic effect of oral hydromorphone. Curr Ther Res Clin Exp 1965, 7:275-283.
51. Nasits B.J. Dental evaluation of hydromorphone (Dilaudid) for oral and maxillo-facial surgery. Tex Dent J 1969, 87:4-6.
52. Sharar S.R., Bratton S.L., Carrougher G.J., et al. A comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. J Burn Care Rehabil 1998, 19:516-521.
53. Drover D.R., Angst M.S., Valle M., et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 2002, 97:827-836.
54. Conley R., Gupta S.K., Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006, 22:1879-1892.
55. Gupta S., Sathyan G. Providing constant analgesia with OROS(R) hydromorphone. J Pain Symptom Manage 2007, 33:S19-S24.
56. Angst M.S., Drover D.R., Lotsch J., et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology 2001, 94:63-73.
57. Moore K.T., St-Fleur D., Marricco N.C., et al. Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study in healthy volunteers. J Opioid Manag 2010, 6:351-358.
58. Richarz U, Vandenbossche J, Kutch M, Moore KT. Characterization of the steady-state pharmacokinetic profile of once-daily hydromorpone ER (OROS hydromorphone ER) versus IR hydromorphone in healthy subjects. Presented at: American Pain Society 30th Annual Scientific Meeting; May 19-21, 2011; Austin, Tex. Poster 336.
59. Richarz U, Vandenbossche J, Kutch M, Moore KT. Pharmacokinetic profile of single-dose once-daily versus IR hydromorphone administered over 24 hours in healthy subjects. Presented at: American Pain Society 30th Annual Scientific Meeting; May 19-21, 2011; Austin, Tex. Poster 335.
60. ® hydromorphone ER) in patients with chronic pain. J Pain Res 2012, 5:523-533.
61. Moore K.T., St-Fleur D., Marricco N.C., et al. A randomized study of the effects of food on the pharmacokinetics of once-daily extended-release hydromorphone in healthy volunteers. J Clin Pharmacol 2011, 51:1571-1579.
62. Babul N., Darke A.C. Putative role of hydromorphone metabolites in myoclonus. Pain 1992, 51:260-261.
63. Fainsinger R., Schoeller T., Boiskin M., Bruera E. Palliative care round: cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 1993, 9:53-55.
64. Weinstein S.M., Shi M., Buckley B.J., Kwarcinski M.A. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain. Clin Ther 2006, 28:86-98.
65. Wallace M., Rauck R.L., Moulin D., et al. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study. Int J Clin Pract 2007, 61:1671-1676.
66. Wallace M., Rauck R.L., Moulin D., et al. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. J Int Med Res 2008, 36:343-352.
67. Palangio M., Northfelt D.W., Portenoy R.K., et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 2002, 23:355-368.
68. Wallace M., Skowronski R., Khanna S., et al. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127). Curr Med Res Opin 2007, 23:981-989.
69. Hanna M., Thipphawong J. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care 2008, 7:17-31.
70. Hale M., Tudor I.C., Khanna S., Thipphawong J. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther 2007, 29:874-888.
71. Binsfeld H., Szczepanski L., Waechter S., et al. A randomized study to demonstrate noninferiority of once-daily OROS(R) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Pract 2010, 10:404-415.
72. Wallace M., Moulin D.E., Rauck R.L., et al. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manag 2009, 5:97-105.
73. Hale M., Khan A., Kutch M., Li S. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin 2010, 26:1505-1518.
74. Wallace M., Thipphawong J. Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain. Pain Med 2010, 11:1477-1488.
75. McPherson M.L. Demystifying Opioid Conversion Calculations: A Guide to Effective Dosing 2010, American Society of Health-System Pharmacist
76. Belle D.J., Singh H. Genetic factors in drug metabolism. Am Fam Physician 2008, 77:1553-1560.
77. Mercadante S., Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 2011, 25:504-515.
78. Gammaitoni A.R., Fine P., Alvarez N., et al. Clinical application of opioid equianalgesic data. Clin J Pain 2003, 19:286-297.
79. Slatkin N.E. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin 2009, 25:2133-2150.
80. Bruera E., Pereira J., Watanabe S., et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996, 78:852-857.
81. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: abuse-deterrent opioids-evaluation and labeling. Draft guidance. Accessed August 6, 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf.
82. Angst M.S., Lazzeroni L.C., Phillips N.G., et al. Aversive and reinforcing opioid effects: A pharmacogenomic twin study. Anesthesiology 2012, 117:22-37.
83. Walsh S.L., Nuzzo P.A., Lofwall M.R., Holtman J.R. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend 2008, 98:191-202.
84. Butler S.F., Black R.A., Cassidy T.A., et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J 2011, 8:29.
85. Marsch L.A., Bickel W.K., Badger G.J., et al. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 2001, 299:1056-1065.
86. Setnik B., Roland C.L., Cleveland J.M., Webster L. The abuse potential of Remoxy(R), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med 2011, 12:618-631.
87. Webster L.R., Bath B., Medve R.A., et al. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone. Pain Med 2012, 13:790-801.
88. Shram M.J., Sathyan G., Khanna S., et al. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol 2010, 30:25-33.
89. Pande P, Hines JW, Brogan P. Tamper-resistant properties of once-daily hydromorphone ER (OROS hydromorphone ER). Presented at: American Pain Society 30th Annual Scientific Meeting; May 19-21, 2011; Austin, Tex. Poster 331.
90. Dart R, Severtson G, Patrick J, Webster L. Abuse, misuse, and diversion of hydromorphone since the introduction of the extended-release formulation (EXALGO®). Presented at: American Pain Society 32nd Annual Scientific Meeting; May 8-11, 2013; New Orleans, La. Poster 419.
91. FDA introduces new safety measures for extended-release and long-acting opioid medications [press release]. July 9, 2012. Silver Spring, Md: US Food and Drug Administration. Accessed April 30, 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm.
92. Slevin K.A., Ashburn M.A. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies. J Opioid Manag 2011, 7:109-115.
93. Johnson F., Wagner G., Sun S., Stauffer J. Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules. J Pain 2008, 9:330-336.
94. Avinza (morphine sulfate) extended-release capsules [package insert]. Bristol, Tenn: King Pharmaceuticals, Inc; 2012.
95. Opana E.R. (oxymorphone hydrochloride) extended-release tablets [package insert] 2012, Endo Pharmaeceuticals, Inc, Chadds Ford, Pa.
96. Fiske W.D., Jobes J., Xiang Q., et al. The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets. J Pain 2012, 13:90-99.
97. Sathyan G., Sivakumar K., Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin 2008, 24:297-305.